Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by CG Oncology Inc.
CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
December 16, 2024
From
CG Oncology Inc.
Via
GlobeNewswire
Tickers
CGON
CG Oncology Announces Pricing of Public Offering
December 12, 2024
From
CG Oncology Inc.
Via
GlobeNewswire
Tickers
CGON
CG Oncology Announces Proposed Public Offering
December 11, 2024
From
CG Oncology Inc.
Via
GlobeNewswire
Tickers
CGON
SUO-CTC and CG Oncology Announce the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
December 06, 2024
From
CG Oncology Inc.
Via
GlobeNewswire
Tickers
CGON
Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
December 05, 2024
From
CG Oncology Inc.
Via
GlobeNewswire
Tickers
CGON
CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Thursday, December 5, 2024
December 02, 2024
From
CG Oncology Inc.
Via
GlobeNewswire
Tickers
CGON
CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 25th Annual Meeting
November 20, 2024
From
CG Oncology Inc.
Via
GlobeNewswire
Tickers
CGON
CG Oncology Reports Third Quarter 2024 Financial Results and Provides Business Updates
November 12, 2024
From
CG Oncology Inc.
Via
GlobeNewswire
Tickers
CGON
CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Muscle-Invasive Bladder Cancer
November 11, 2024
From
CG Oncology Inc.
Via
GlobeNewswire
Tickers
CGON
CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
August 30, 2024
From
CG Oncology Inc.
Via
GlobeNewswire
Tickers
CGON
CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates
August 08, 2024
From
CG Oncology Inc.
Via
GlobeNewswire
Tickers
CGON
CG Oncology Initiates Expanded Access Program for Cretostimogene Grenadenorepvec
June 18, 2024
From
CG Oncology Inc.
Via
GlobeNewswire
Tickers
CGON
CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC
June 06, 2024
From
CG Oncology Inc.
Via
GlobeNewswire
Tickers
CGON
CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting
May 24, 2024
From
CG Oncology Inc.
Via
GlobeNewswire
Tickers
CGON
CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates
May 09, 2024
From
CG Oncology Inc.
Via
GlobeNewswire
Tickers
CGON
Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
May 03, 2024
From
CG Oncology Inc.
Via
GlobeNewswire
Tickers
CGON
CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024
April 26, 2024
From
CG Oncology Inc.
Via
GlobeNewswire
Tickers
CGON
CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024
April 24, 2024
From
CG Oncology Inc.
Via
GlobeNewswire
Tickers
CGON
CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual Meeting
March 28, 2024
From
CG Oncology Inc.
Via
GlobeNewswire
Tickers
CGON
CG Oncology Announces First Patient Dosed in PIVOT-006 Phase 3 Clinical Trial of Cretostimogene in Intermediate-risk Non-Muscle Invasive Bladder Cancer
February 27, 2024
From
CG Oncology Inc.
Via
GlobeNewswire
Tickers
CGON
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.